NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Bank of America Securities 2024 Health Care Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Tuesday, May 14, 2024 at 4:20 p.m. PT in Las Vegas.

NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually.

NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on April 1, 2024, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. Shares of Worthington Steel, Inc. (NYSE: WS) rose sharply during Friday’s session as the company posted stronger-than-expected results for its third quarter. Worthington Steel posted adjusted earnings of 99 cents per share, beating market estimates of 84 cents per share. The company’s quarterly sales came in at $805.80 million, versus expectations of $700.50 million, according to data from Benzinga Pro. Worthington Steel shares jumped 18.8% to $37.92 on Friday. Here are some other big stocks recording gains in today’s session. Murano Global Investments PLC (NASDAQ: MRNO) shares gained 147.5% to $23.94 after falling 46% on ...

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1’24 with top-line results anticipated in 2H’25

NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

Across the recent three months, 4 analysts have shared their insights on Dianthus Therapeutics (NASDAQ:DNTH), expressing a variety of opinions spanning from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 1 0 0 0 Analysts have set 12-month price targets for Dianthus Therapeutics, revealing an average target of $28.25, a high estimate of $44.00, and a low estimate of $22.00. Observing a 22.83% increase, the current average has risen from the previous average price target of $23.00. Understanding Analyst Ratings: A Comprehensive Breakdown The analysis of recent analyst actions sheds light on the perception of Dianthus Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Alex Thompson Stifel Announces Buy $44.00 - Laura Chico Wedbush Raises Outperform $24.00 $23.00 Maury Raycroft Jefferies Announces Buy $22.00 - Laura Chico Wedbush Announces Outperform $23.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects ...Full story available on Benzinga.com